VivoSim Labs, Inc. Common Stock
$0.26
-$0.00 (-1.14%)
$0.26Day Range$0.27
Key Statistics
Market Cap
$3.51M
Shares Outstanding
13.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 16, 2011
Round Lot
100
Locale
US
Trading Data
Day Open
$0.27
Day High
$0.27
Day Low
$0.26
Volume
597.8K
VWAP
$0.27
Prev Close
$0.26
Transactions
--
Acc. Volume
--
About VivoSim Labs, Inc. Common Stock
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283611 employees11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121858-224-1000IPO Aug 16, 2011US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001497253
- Composite FIGI
- BBG001M8GFD0
- Share Class FIGI
- BBG001V10TP9
- Ticker Root
- VIVS
- SIC Code
- 2836
About VivoSim Labs, Inc. Common Stock (VIVS) Stock
VivoSim Labs, Inc. Common Stock (VIVS) closed the 2026-09-17 session at $0.26, down 1.14% versus the previous close (-0.00). The stock opened at $0.27 and traded between $0.26 and $0.27 during that session. Session trading volume was 598K shares. The volume-weighted average price (VWAP) is $0.27.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
VivoSim Labs, Inc. Common Stock has a market capitalization of $3.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. VIVS is listed on the XNAS exchange. The company employs approximately 11 people. VivoSim Labs, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2011-08-16.
On this page you can find market VIVS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.